Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This research found that a novel dehydroepiandrosterone derivative (12) significantly reduces cell viability and increases apoptosis in testosterone-stimulated normal and tumor prostate cells, unlike finasteride and dutasteride, which also showed activity under dihydrotestosterone stimulation.

This study found that two synthesized androst-4-ene-3-one derivatives, 6f and 6g, exhibited stronger anti-proliferative effects than common drugs on prostate cancer cell lines, with low toxicity to rat cells.

In this study, FMN was found to inhibit androgen receptor function and androgen-regulated gene expression in prostate cancer cells, suggesting potential as an antiandrogen therapy.

The study created a test that found hormonal and toxic effects in plant and fungal extracts using prostate cancer cells.

This study found that Phyllanthus urinaria extract displayed significant anti-alopecia properties in a mouse model, showing potential as an anti-5α-reductase agent for androgenic hair loss.

This study found that unripe Rubus occidentalis extracts may inhibit benign prostatic hyperplasia development in a rat model by reducing prostate weight and androgen-related gene expression.

This study found that PLX, a mixture of tomato extract and chitooligosaccharide, may reduce prostate weight in testosterone-induced BPH in rats, suggesting it could act as a 5α-reductase inhibitor.

In this study, osthenol was identified as a highly potent inhibitor of 5alpha-reductase type I in LNCaP cells, significantly outperforming finasteride.

This study found that some synthesized heterocyclic derivatives showed promising 5α-reductase inhibitor, antiviral, and anti-tumor activities, surpassing several reference drugs in effectiveness.

This study identified compounds 11d and 11k as potential dual 5α-reductase inhibitors and AR antagonists with significant anti-proliferative effects on prostate cancer cell lines, suggesting they may offer therapeutic value.

This study found that 2-methoxyestradiol induces apoptosis in human prostate cancer cells by activating p53 through a pathway dependent on p38/JNK-mediated NFkappaB/AP-1 activation, with JNK-dependent Bcl-2 phosphorylation also playing a critical role.

This study found that the co-activator CBP enhances the agonistic action of hydroxyflutamide on androgen receptors, suggesting a mechanism for therapy resistance in prostate cancer.

Dutasteride may help treat prostate cancer by causing cancer cells to shrink and die.

In this study, saw palmetto supplements showed varied effects on cell growth in vitro and did not significantly inhibit growth in the hamster flank organ model despite a notable trend.

This study suggests that passage number significantly affects in silico scratch assay results, highlighting the importance of reporting passage number for reproducibility in cell culture experiments.

This study found that dutasteride more effectively inhibited androgen receptor signaling and reduced cell growth compared to finasteride in prostate cancer cell models, with varying sensitivities across different cell lines.

In this study, researchers developed a sensitive assay to measure the inhibition of steroid 5-α reductase (5AR) by chemicals like finasteride and dutasteride, revealing species-specific differences in inhibitor efficacy between human and fish cell lines.

This study identified 30 new compounds with significant androgen receptor binding affinity through a combination of virtual screening and in vitro testing.

This study found that overexpression of AKR1C3 in prostate cancer cells redirected androgen metabolism towards testosterone production, which facilitated cell proliferation, potentially reducing the effectiveness of finasteride treatment.

This study demonstrated that derivatives of dehydroepiandrosterone (2a-b, 3a-f, and 4a-f) significantly reduced viable LNCaP prostate cancer cells, suggesting potential therapeutic use for metastatic prostate cancer, while finasteride did not alter cell viability.

This study found that finasteride decreased DHT-stimulated AR activity and cell growth in prostate cancer cells with mutant AR, but not in those with wild type AR.

This study found that Ganoderma lucidum extracts showed weak 5alpha-reductase inhibition but significantly inhibited prostate cell proliferation and testosterone-driven prostate growth in rats, suggesting potential as an ingredient for treating androgen-induced diseases.

This study found that AR/VDR-targeted agonist hormone therapy can inhibit cell viability in HR2-av triple-negative breast cancer cell lines through multiple mechanisms and may enhance the effects of chemotherapy.

This study found that the pharmacological inhibition of 5-α reductases with finasteride and dutasteride can reduce neurosteroid synthesis in glioblastoma-derived cell lines, potentially impacting GBM survival.

This review discusses the potential of plant-derived phytochemicals as alternatives to 5-alpha-Reductase inhibitors in treating prostate cancer, highlighting possible benefits like reduced side effects, but it reports no new findings.

This study reported that the novel AKT inhibitor CCT128930 demonstrated significant antitumor activity in human cancer cell lines and xenografts, highlighting its potential as an anticancer therapy.

This study found that minoxidil and ranolazine, individually and in combination, reduced cellular invasiveness in hypoxic triple-negative breast cancer cell lines, suggesting potential anti-metastatic effects at clinically relevant doses.

This study suggests that the adrenal gland may contribute to prostate cancer treatment resistance and indicates potential steroid production or dependency in ovarian cancer.

In this study, Trapa bispinosa Roxb. pericarp extract demonstrated inhibitory effects on 5α-reductase activity both in vitro using LNCaP cells and in vivo in a mouse model of benign prostatic hyperplasia, suggesting its potential role in managing the condition.